ANRO trades 34.6% below Wall Street's consensus target of $34.60.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ANRO achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Alto Neuroscience, Inc. (ANRO) has a Wall Street consensus price target of $34.60, based on estimates from 8 covering analysts. With the stock currently trading at $25.70, this represents a potential upside of +34.6%. The company has a market capitalization of $902M.
Analyst price targets range from a low of $24.00 to a high of $50.00, representing a 75% spread in expectations. The median target of $35.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ANRO trades at a trailing P/E of -11.7x. Analysts expect EPS to grow -32.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
SAVACassava Sciences, Inc. | $64M | $1.32 | — | — | Buy | — | 12 |
NRXPNRx Pharmaceuticals, Inc. | $72M | $4.16 | — | — | — | — | — |
INVAInnoviva, Inc. | $1.6B | $22.25 | $37.00 | +66.3% | Buy | 6.2x | 10 |
ACADACADIA Pharmaceuticals Inc. | $4.5B | $26.20 | $34.38 | +31.2% | Buy | 68.9x | 37 |
AXSMAxsome Therapeutics, Inc. | $12.9B | $249.76 | $262.38 | +5.1% | Buy | — | 26 |
INTRInter & Co, Inc. | $2.5B | $5.59 | $9.40 | +68.2% | Buy | 1.4x | 6 |
PRAXPraxis Precision Medicines, Inc. | $9.4B | $323.95 | $589.00 | +81.8% | Buy | — | 16 |
ILMNIllumina, Inc. | $29.1B | $191.76 | $156.27 | -18.5% | Buy | 36.6x | 50 |
TMOThermo Fisher Scientific Inc. | $192.0B | $516.62 | $592.45 | +14.7% | Buy | 20.8x | 42 |
CRLCharles River Laboratories International, Inc. | $11.0B | $228.68 | $222.11 | -2.9% | Buy | 20.6x | 37 |
Quick answers to the most common questions about buying ANRO stock.
The consensus Wall Street price target for ANRO is $34.6, representing 34.6% upside from the current price of $25.7. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ANRO has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $34.6 implies 34.6% upside from current levels.
ANRO's current price is $25.7 with a consensus target of $34.6 (34.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $50 for ANRO, while the most conservative target is $24. The consensus of $34.6 represents the median expectation. These targets typically reflect 12-month expectations.
ANRO is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ANRO stock forecast based on 8 Wall Street analysts shows a consensus price target of $34.6, with estimates ranging from $24 (bear case) to $50 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ANRO, with a "Buy" consensus rating and $34.6 price target (34.6% upside). 7 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ANRO analyst price targets range from $24 to $50, a 75% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $34.6 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.